ClinicalTrials.gg
Drug

Carfilzomib clinical trials

Also written Kyprolis and PR-171.

studies test it
157
open now
18
in phase 3
15
first study started
2005

How each study uses carfilzomib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the carfilzomib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 Jul 2012 · KYPROLIS · NDA 202714 (FDA, Drugs@FDA)
European Union
19 Nov 2015 · Kyprolis · EMEA/H/C/003790 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Carfilzomib
141
Krypolis
6
Kyprolis® (carfilzomib) for Injection
6
CFZ
5
Carfilnat
2

Brand

Kyprolis
79

Development codes

PR-171
45
PX-171-007
1

In one entry with another drug

Given together, or one or the other

CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
2

Studies by the year they started

157 studies that test it; most in 2013 (22)

Studies that test carfilzomib, by start year
YearStudies
20051
20073
20082
20092
20106
201110
201211
201322
201417
201512
20164
201710
20188
201914
20206
20217
20225
20236
20243
20253
20265

Who runs them

Industry 38 · Other 119

Amgen (23) · M.D. Anderson Cancer Center (9) · University of Chicago (7) · National Cancer Institute (NCI) (5) · Hackensack Meridian Health (5) · Memorial Sloan Kettering Cancer Center (5) · Emory University (5) · Mayo Clinic (4)

Often tested with

Tested in the same studies.

Dexamethasone (69) · Lenalidomide (25) · Daratumumab (18) · Pomalidomide (15) · Cyclophosphamide (11) · Melphalan (6) · Bortezomib (5) · Isatuximab (5)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 5 phase 3 studies under way

Carfilzomib is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 20, 3 in phase 3

Studies that test carfilzomib, phase 3 first.

Studies

Open first, then newest update. How each study uses carfilzomib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 157

See all 157 studies that test carfilzomib →

Given beside what is tested · 58 — carfilzomib is usual care or a partner of the new treatment

Showing 20 of 58.

As the comparator · 8 — what is tested is compared with carfilzomib

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call carfilzomib · ClinicalTrials.gg INT005194

  • MeSH (NLM) C524865carfilzomibOne source NLM
  • UNII (FDA) 72X6E3J5ARCARFILZOMIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1302966Confirmed FDA, Wikidata
  • Wikidata Q15366934carfilzomibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C52196CarfilzomibOne source FDA
  • DrugBank DB08889One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.